DR Congo launches trial of Ebola vaccine against Bundibugyo strain

Researchers in the Democratic Republic of Congo have begun testing the Ervebo vaccine as a potential countermeasure to the Bundibugyo Ebola virus strain, which has circulated with limited medical interventions available to contain its spread.

The outbreak response effort has been significantly constrained by the absence of approved treatments specifically designed for the Bundibugyo variant, one of four known Ebola species. By evaluating whether Ervebo, an existing vaccine approved for other Ebola strains, can provide cross-protective immunity, health officials aim to expand their therapeutic toolkit during the epidemic.

Ervebo, developed by Merck, has demonstrated effectiveness against the Zaire strain of Ebola virus and has been deployed in previous outbreak response efforts. The trial in DR Congo will generate critical data on whether the vaccine's protection extends to the Bundibugyo strain, potentially offering a validated prevention strategy for future outbreaks or current transmission chains.

The initiation of the vaccine trial underscores the ongoing challenges in managing Ebola outbreaks in Central Africa, where rapid diagnostic and treatment capabilities remain limited. Authorities hope the trial results will provide evidence-based guidance for outbreak response protocols across the region.